Advertisement
Organisation › Details
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *
Start | 1992-01-01 established | |
Group | MorphoSys (Group) | |
Predecessor | MorphoSys GmbH | |
Industry | biopharmaceutical | |
Person | Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme) | |
Person 2 | Lee, Sung (MorphoSys 202102–202303 CFO before Sangamo + Gilead Sciences LEFT 3/23) | |
Region | Martinsried | |
Country | Germany | |
Street | 7 Semmelweisstr. | |
City | 82152 Planegg | |
Tel | +49-89-89927-0 | |
Address record changed: 2022-09-17 | ||
Basic data | Employees | E: 501 to 1,000 (2022-12-31) |
Currency | EUR | |
Annual sales | 278,267,003 (revenues, consolidated (2022) 2022-12-31) | |
Profit | -151,058,190 (2022-12-31) | |
Cash | 402,350,904 (2022-12-31) | |
* Document for »About Section«: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for MorphoSys (Group)
- [1] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
- [2] MorphoSys AG. (12/14/23). "Press Release: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million [Not for US, AU, ZA, JP, et al.]". Planegg....
- [3] MorphoSys AG. (5/3/23). "Press Release: MorphoSys AG Reports First Quarter 2023 Financial Results". Planegg....
- [4] MorphoSys AG. (3/14/23). "Press Release: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer". Planegg....
- [5] MorphoSys AG. (3/2/23). "Press Release: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs". Planegg....
- [6] MorphoSys AG. (12/20/22). "Press Release: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023". Planegg....
- [7] MorphoSys AG. (12/6/22). "Press Release: MorphoSys Out Licenses Pre-Clinical Oncology Program". Planegg....
- [8] Roche. (11/14/22). "Press Release: Roche Provides Update on Phase III GRADUATE Programme Evaluating Gantenerumab in Early Alzheimer’s Disease". Basel....
- [9] MorphoSys AG. (11/14/22). "Press Release: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease". Planegg....
- [10] MorphoSys AG. (10/27/22). "Press Release: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis". Planegg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top